



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

January 26, 2022

Gavin Choy
Acting Chief Financial Officer
GT Biopharma, Inc.
9350 Wilshire Blvd
Suite 203
Beverly Hills, CA 90212

Re: GT Biopharma, Inc.
Form 10-K for the period ended December 31, 2020
Filed April 16, 2021
Form 10-Q for the period ended June 30, 2021
Filed August 23, 2021
Form 10-Q for the period ended September 30, 2021
Filed November 10, 2021
File No. 001-40023

Dear Mr. Choy:

We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance
Office of Life Sciences